In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

Core Insights - N2OFF, Inc. is focusing on drug discovery and solar energy investments, highlighting a peer-reviewed study on mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunctions [1][2][4] Group 1: Study Overview - The study titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction" was published on December 30, 2025, and examines the expression of 53 SLC25A genes under microgravity conditions [2][3] - The analysis found differential regulation of SLC25A carriers, suggesting their potential as biomarkers for mitochondrial dysfunction [3] Group 2: Company Focus - MitoCareX Bio, a subsidiary of N2OFF, is developing small-molecule drugs targeting mitochondrial carriers, which are crucial for cellular energy metabolism and are involved in various diseases [4][6] - The company utilizes proprietary methods, including the MITOLINE algorithm, to model and validate drug targets within the SLC25A family [4] Group 3: Investment Strategy - N2OFF is also investing in European renewable energy assets, specifically solar projects, under a Ready to Build (RTB) business model [6] - The company is the lead investor in four solar projects across three EU countries, introduced by its subsidiary Solterra Renewable Energy Ltd [6]